FDA extends approval of Humira in JIA - AbbVie

The FDA has approved the extension of the indication for Humira (adalimumab), from AbbVie, for moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. Humira was approved in the United States in 2008 for polyarticular JIA in patients ages 4 and older. Humira will be available to patients ages 2 and older living with polyarticular JIA with the dose based on patient weight. Humira is available for this patient population in a 10 mg pre-filled syringe, 20 mg pre-filled syringe, 40 mg pre-filled syringe and 40 mg Humira auto-injector pen.